MINI FUTURE SHORT - NOVO-NORDISK B | Real-time Bid/Ask 04:08:44 2024-06-04 EDT | ||
| 1.1 CHF / 1.11 CHF | -2.21% |
|
| 1 month | -16.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.13 | -5.04% |
| 24-05-30 | 1.19 | -2.46% |
| 24-05-29 | 1.22 | +1.67% |
| 24-05-28 | 1.2 | +1.69% |
| 24-05-27 | 1.18 | +6.31% |
Delayed Quote Swiss Exchange
Last update May 31, 2024 at 11:20 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| VKFABP | |
| ISIN | CH1332890883 |
| Date issued | 2024-03-07 |
| Strike | 1,097 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.62 CHF |
|---|---|
| Lowest since issue | 1.06 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.90% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.2
DKK
Spread / Average Target
-0.72%
- Stock Market
- Certificates
- VKFABP Certificat
